Blog

Jul 31, 2024, 08:54

Akhil Kapoor: Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals

Akhil Kapoor, Associate Professor and Medical Oncology at TMH Varanasi, shared a post on X about a recent paper titled “Docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus Oxaliplatin-Capecitabine/5 fluorouracil (CAPOX/mFOLFOX-7) in HER2 negative advanced gastric cancers” published on JNCI.

Authors: Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, Anuj Gupta, Akhil Kapoor, Sujay Srinivas, Omshree Shetty, Poonam Jadhav, et al.

“Our Multicenter study led by Vikas Ostwal and Anant Ramaswamy published in JNCI.

Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals
Increases toxicities
More is NOT always better.

Genomic Profiling revealed:

Low incidence of microsatellite instability (1%)
High incidence of BRCA1 (7.5%) and BRCA2 (8.4%) somatic alterations. Implications??”

Source: Akhil Kapoor/X

Akhil Kapoor Anant Ramaswamy Anuj Gupta Biswajit Dubashi BRCA1 BRCA2 cancer JNCI Omshree Shetty OncoDaily Oncology Poonam Jadhav Prabhat Bhargava somatic alterations Sujay Srinivas Vikas Ostwal

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer